These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 25546091

  • 1. Low and fixed dose of hydroxyurea is effective and safe in patients with HbSβ(+) thalassemia with IVS1-5(G→C) mutation.
    Dehury S, Purohit P, Patel S, Meher S, Kullu BK, Sahoo LK, Patel NK, Mohapatra AK, Das K, Patel DK.
    Pediatr Blood Cancer; 2015 Jun; 62(6):1017-23. PubMed ID: 25546091
    [Abstract] [Full Text] [Related]

  • 2. The effect of hydroxyurea on compound heterozygotes for sickle cell-hemoglobin D-Punjab--a single centre experience in eastern India.
    Patel S, Purohit P, Mashon RS, Dehury S, Meher S, Sahoo S, Dash SS, Das K, Das P, Patel DK.
    Pediatr Blood Cancer; 2014 Aug; 61(8):1341-6. PubMed ID: 24616059
    [Abstract] [Full Text] [Related]

  • 3. Hydroxyurea in sickle cell disease--a study of clinico-pharmacological efficacy in the Indian haplotype.
    Italia K, Jain D, Gattani S, Jijina F, Nadkarni A, Sawant P, Nair S, Mohanty D, Ghosh K, Colah R.
    Blood Cells Mol Dis; 2009 Aug; 42(1):25-31. PubMed ID: 18954999
    [Abstract] [Full Text] [Related]

  • 4. Low dose hydroxyurea is effective in reducing the incidence of painful crisis and frequency of blood transfusion in sickle cell anemia patients from eastern India.
    Patel DK, Mashon RS, Patel S, Das BS, Purohit P, Bishwal SC.
    Hemoglobin; 2012 Aug; 36(5):409-20. PubMed ID: 22881992
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Optimizing Hydroxyurea use in children with sickle cell disease: low dose regimen is effective.
    Sharef SW, Al-Hajri M, Beshlawi I, Al-Shahrabally A, Elshinawy M, Zachariah M, Mevada ST, Bashir W, Rawas A, Taqi A, Al-Lamki Z, Wali Y.
    Eur J Haematol; 2013 Jun; 90(6):519-24. PubMed ID: 23489171
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Children with HbSβ0 thalassemia have higher hemoglobin levels and lower incidence rate of acute chest syndrome compared to children with HbSS.
    Day ME, Rodeghier M, DeBaun MR.
    Pediatr Blood Cancer; 2018 Nov; 65(11):e27352. PubMed ID: 30094930
    [Abstract] [Full Text] [Related]

  • 9. Neurocognitive functioning in preschool children with sickle cell disease.
    Heitzer AM, Cohen DL, Okhomina VI, Trpchevska A, Potter B, Longoria J, Porter JS, Estepp JH, King A, Henley M, Kang G, Hankins JS.
    Pediatr Blood Cancer; 2022 Mar; 69(3):e29531. PubMed ID: 34971013
    [Abstract] [Full Text] [Related]

  • 10. Beneficial Effect of Low Fixed Dose of Hydroxyurea in Vaso-occlusive Crisis and Transfusion Requirements in Adult HbSS Patients: A Prospective Study in a Tertiary Care Center.
    Sethy S, Panda T, Jena RK.
    Indian J Hematol Blood Transfus; 2018 Apr; 34(2):294-298. PubMed ID: 29622872
    [Abstract] [Full Text] [Related]

  • 11. Hydroxyurea in the treatment of major beta-thalassemia and importance of genetic screening.
    Alebouyeh M, Moussavi F, Haddad-Deylami H, Vossough P.
    Ann Hematol; 2004 Jul; 83(7):430-3. PubMed ID: 14722738
    [Abstract] [Full Text] [Related]

  • 12. Clinical response and adverse events in young patients with sickle cell disease treated with hydroxyurea.
    Kattamis A, Lagona E, Orfanou I, Psichou F, Ladis V, Kanavakis E, Metaxotou-Mavrommati A, Kattamis C.
    Pediatr Hematol Oncol; 2004 Jun; 21(4):335-42. PubMed ID: 15205096
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Hematologic response to hydroxyurea therapy in children with beta-thalassemia major.
    Mtvarelidze Z, Kvezereli-Kopadze A, Kvezereli-Kopadze M, Mestiashvili I.
    Georgian Med News; 2008 Mar; (156):91-4. PubMed ID: 18403819
    [Abstract] [Full Text] [Related]

  • 16. Hydroxyurea therapy for diverse pediatric populations with sickle cell disease.
    Rogers ZR.
    Semin Hematol; 1997 Jul; 34(3 Suppl 3):42-7. PubMed ID: 9317200
    [Abstract] [Full Text] [Related]

  • 17. Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease.
    Jain DL, Sarathi V, Desai S, Bhatnagar M, Lodha A.
    Hemoglobin; 2012 Jul; 36(4):323-32. PubMed ID: 22734586
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of hydroxyurea in providing transfusion independence in β-thalassemia.
    Ansari SH, Shamsi TS, Ashraf M, Perveen K, Farzana T, Bohray M, Erum S, Mehboob T.
    J Pediatr Hematol Oncol; 2011 Jul; 33(5):339-43. PubMed ID: 21602718
    [Abstract] [Full Text] [Related]

  • 19. The effect of hydroxyurea on the coagulation system in sickle cell anemia and beta-thalassemia intermedia patients: a preliminary study.
    Koc A, Gumruk F, Gurgey A.
    Pediatr Hematol Oncol; 2003 Sep; 20(6):429-34. PubMed ID: 14631615
    [Abstract] [Full Text] [Related]

  • 20. Hydroxyurea in thalassemia intermedia--a promising therapy.
    Dixit A, Chatterjee TC, Mishra P, Choudhry DR, Mahapatra M, Tyagi S, Kabra M, Saxena R, Choudhry VP.
    Ann Hematol; 2005 Jul; 84(7):441-6. PubMed ID: 15838670
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.